Page 26 - ARNM-3-3

Advances in Radiotherapy
& Nuclear Medicine Brachytherapy versus external beam in local dose escalation

Table 3. Summary of endometrial cancer studies
Authors Study n pts Treatment Target coverage Dose to OAR Main results
Pinzi Retr 15 IMRT vs. CI IMRT: IMRT: IMRT showed superior tumor control and dose
et al. 16 HDR-IRT 0.97±0.01; Rectum D2cm 89.54%; homogeneity compared to IRT; however, IRT
3
CI IRT: Bowel D2cm 91.15%; resulted in lower doses to OAR
3
0.73±0.17; Bladder D2cm 78.57%
3
CN IMRT: IRT:
0.78±0.10; Rectum D2cm 47.95%;
3
CN IRT: Bowel D2cm 39.12%;
3
0.24±0.15; Bladder D2cm 30.95%
3
TCP IMRT:
99.51±0.88;
TCP IRT:
80.13±25.10
Cilla Retr 8 HDR-IRT CTV Dmean FI-VMAT: D0.1cc rectum FI-VMAT: PO-VMAT provided the best target coverage
et al. 17 vs. 108.6%; 112.0%; (D99% of 112.6%) and reduced doses to the
PO-VMAT CTV Dmean PO-VMAT: D0.1cc rectum PO-VMAT: rectum and bladder compared to HDR-IRT.
vs. 118.5%; 112.0%; HDR-IRT delivered lower doses to the femoral
FI-VMAT CTV Dmean HDR-IRT: D0.1cc rectum HDR-IRT: heads but was associated with greater dose
144.2%; 131.2%; heterogeneity
CTV EUD FI-VMAT: D0.1cc bladder FI-VMAT:
111.0%; 129.2%;
CTV EUD PO-VMAT: D0.1cc bladder PO-VMAT:
130.0%; 108.7%;
CTV EUD IRT: D0.1cc bladder HDR-IRT:
136.9%; 129.2%
Grelewicz Retr 4 IMRT vs. Mean CTV dose IMRT: IMRT: HDR-IRT plans demonstrated superior normal
et al. 18 HDR-IRT 14.8; D2cc bladder 10.76; tissue sparing
Mean CTV dose IRT D1cc bladder 11.61;
14.9 D0.1cc bladder 13
IRT:
D2cc bladder 7.77;
D1cc bladder 8.93;
D0.1cc bladder 10.72
IMRT:
D2cc rectum 8.84;
D1cc rectum 10.12;
D0.1cc rectum 12.72
IRT:
D2cc rectum 6.57;
D1cc rectum 7.6;
D0.1cc rectum 9.96
IMRT:
D2cc sigmoid 7.91;
D1cc sigmoid 8.97;
D0.1cc sigmoid 11.13
IRT:
D2cc sigmoid 6.08;
D1cc sigmoid 7.08;
D0.1cc sigmoid 10.39
Abbreviations: CI: Conformity index; CN: Conformation number; CTV: Clinical target volume; EUD: Equivalent uniform dose;
HDR: High-dose rate; FI: Full-inverse planning module; IMRT: Intensity-modulated radiotherapy; IRT: Interventional radiotherapy; n: Number;
PO: Anatomy-based optimization module; pts: Patients; Retr: Retrospective; TCP: Tumor control probability; VMAT: Volumetric modulated arc
therapy; vs.: Versus.

time from the initiation of the IRT or EBRT boost to death, and death from any cause or last follow-up. DMFS was
specifically attributable to the disease. OS was defined as defined as the time from the start of boost treatment to the
the interval between the start of the IRT or EBRT boost detection of disease progression outside the irradiated field

Volume 3 Issue 3 (2025) 18 doi: 10.36922/ARNM025160017